Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Ho

Anesthesiology Danvers, MA Medical Doctor

NPI 1013998269 CMS profile 961845

75 Lindall St, Danvers, MA 01923

Open in the dashboard

General payments

$6,953

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Ho of Danvers, MA is reported in the CMS Open Payments database as having received $6,953 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,315 22
2024 General $424 10
2023 General $2,898 37
2022 General $510 5
2021 General $683 8
2019 General $123 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Ho
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Charles Ho were reported at $2,315. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Charles Ho Anesthesiology median Middle half National median
2019 $123 $72 $23–$151 $163
2020 $0 $36 $17–$120 $114
2021 $683 $49 $21–$135 $132
2022 $510 $52 $22–$144 $149
2023 $2,898 $53 $23–$143 $160
2024 $424 $55 $25–$150 $164
2025 $2,315 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $2,122 21 payments
  2. Abbott Laboratories $1,894 12 payments
  3. Nevro Corp. $1,099 19 payments
  4. Boston Scientific Corporation $383 8 payments
  5. Vertos Medical, Inc. $286 5 payments
  6. Medtronic, Inc. $262 3 payments
  7. Painteq LLC $244 4 payments
  8. AcelRx Pharmaceuticals, Inc. $123 1 payment
  9. Nalu Medical, Inc. $120 1 payment
  10. Avanos Medical $101 1 payment
  11. Other $317 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,300 70 payments
  2. Travel and Lodging $2,653 13 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $2,122 21 payments
  2. Intracept Pain $1,846 18 payments
  3. Intracept Pain $1,846 18 payments
  4. Intracept Pain $1,846 18 payments
  5. PROCLAIM $1,676 10 payments
  6. Senza $824 17 payments
  7. mild Device Kit $286 5 payments
  8. Intracept Pain $277 3 payments
  9. Omnia $275 2 payments
  10. PAINTEQ $244 4 payments
  11. Other $1,637 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

824

Median for Anesthesiology: 322

Drug cost

$14,174

Median for Anesthesiology: $8,738

Branded share of claims

26.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 28 $3,044
Gabapentin Generic 203 $2,261
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 115 $2,165
Oxycodone Hcl Generic 101 $1,502
Pregabalin Generic 48 $1,213
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 64 $1,039
Morphine Sulfate Er Morphine Sulfate Brand 24 $652
Diclofenac Sodium Generic 32 $583
Cyclobenzaprine Hcl Generic 48 $483
Tramadol Hcl Generic 86 $310

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$93,245

Of which drugs: $188

Medicare patients

381

Average age 74

Services billed

1,366

219 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 31%
Ischemic heart disease 31%
Chronic kidney disease 30%
COPD 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 192 $147
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 32 45 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record